Ki-67 and Histological Grade in Breast Cancer

Mirela Pirić; Edin Jusufović; Hasan  Osmić; Begzada Hasukić; Rifat Sejdinović; Nehra Mosorovic; Selmira Brkić; Besim  Prnjavorac

doi:10.3889/oamjms.2024.11974

Authors

Mirela Pirić Department of General Surgery, Public Health “Health Center of Brčko”, Brčko, Bosnia and Herzegovina https://orcid.org/0009-0005-0416-5843
Edin Jusufović Health and Educational Institution “Dr. Mustafa Sehovic”, Centre for Specific and Non-Specific Lung Diseases, Tuzla, Bosnia and Herzegovina; Department of Internal Medicine, University in Tuzla, Faculty of Medicine; Tuzla, Bosnia and Herzegovina https://orcid.org/0000-0003-2441-9888
Hasan Osmić Department of Internal Medicine, University in Tuzla, Faculty of Medicine; Tuzla, Bosnia and Herzegovina; Department for Radiotherapy, University Clinical Centar of Tuzla; Tuzla, Bosnia and Herzegovina https://orcid.org/0009-0009-1428-6285
Begzada Hasukić Department of Internal Medicine, University in Tuzla, Faculty of Medicine; Tuzla, Bosnia and Herzegovina; Clinic for Otoryngology, Cervical and Maxillofacial Surgery, Tuzla, Bosnia and Herzegovina https://orcid.org/0000-0002-8239-8395
Rifat Sejdinović Department of Internal Medicine, General Hospital Institution Tesanj, Tesanj, Bosnia and Herzegovina; Department of Internal Medicine, University in Zenica, Faculty of Medicine; Zenica, Bosnia and Herzegovina https://orcid.org/0009-0005-0708-0634
Nehra Mosorovic Departments for Occupational Medicine, Health Medical Centre Lukavac, Lukavac, Bosnia and Herzegovina https://orcid.org/0009-0000-6072-0788
Selmira Brkić Department of Internal Medicine, University in Tuzla, Faculty of Medicine; Tuzla, Bosnia and Herzegovina https://orcid.org/0009-0002-9483-0701
Besim Prnjavorac Department of Internal Medicine, General Hospital Institution Tesanj, Tesanj, Bosnia and Herzegovina; Department of Internal Medicine, University in Zenica, Faculty of Medicine; Zenica, Bosnia and Herzegovina

DOI:

https://doi.org/10.3889/oamjms.2024.11974

Keywords:

Breast neoplasms, Cell proliferation, Immunohistochemistry, Prognostic factors

Abstract

AIMS: The aim of the study was to investigate the prognostic value of Ki-67 and histological grade in patients with estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative early breast cancer. Although the proliferation activity of different tumors assessed with antigen Ki-67 was extensively studied in the last decade and showed that Ki67 expression was a useful prognostic factor in breast cancer, there is still a controversy about the utility value of Ki-67.

METHODS: The retrospective study covered the period from 2016 to 2022. Year included 106 patients from Brcko District, with early estrogen-positive and HER2 receptors-negative breast cancer. The average patients’ age was 62.37 ± 11.65 years. Patients were divided into groups with high/low Ki-67 and high/low histological grade. Multiple linear regression analysis was performed for disease relapse and mortality.

RESULTS: Patients with high Ki-67 were more frequent postmenopausal, had higher histological grade, cancer ˂2 cm, more frequent lymph nodes’ metastases, more frequently underwent to axillary surgery, and had a higher mortality rate. Patients with high histological grade were older, more frequent postmenopausal, had more frequent metastases to the lymph nodes, more frequent occurrence of high Ki-67, more frequent relapse of disease, and more frequent of death.

CONCLUSION: Combination of high Ki-67 with high histological grade in ER positive and HER2-negative early breast cancer is an important prognostic factor.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Lau J, Shrestha P, Shaina Ng J, Jianlin Wong G, Legido- Quigley H, Tan KK. Qualitative factors influencing breast and cervical cancer screening in women: A scoping review. Prev Med Rep. 2022;27:101816. https://doi.org/10.1016/j.pmedr.2022.101816 PMid:35656228

Cserni B, Bori R, Csörgő E, Oláh-Németh O, Pancsa T, Sejben A, et al. The additional value of ONEST (Observers Needed to Evaluate Subjective Tests) in assessing reproducibility of oestrogen receptor, progesterone receptor, and Ki67 classification in breast cancer. Virchows Arch. 2021;479(6):1101-9. https://doi.org/10.1007/s00428-021-03172-9 PMid:34415429

Turner BM, Katerji H, Zhang H, Hicks DG. Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach. Hum Pathol Rep. 2021;26:300574. https://doi.org/10.1016/j.hpr.2021.300574

Finkelman BS, Zhang H, Hicks DG, Turner BM. The evolution of Ki-67 and breast carcinoma: Past observations, present directions, and future considerations. Cancers (Basel). 2023;15(3):808. https://doi.org/10.3390/cancers15030808 PMid:36765765

Yadav S, Zhou S, He B, Du Y, Garmire LX. Deep learning and transfer learning identify breast cancer survival subtypes from single-cell imaging data. Commun Med (Lond). 2023;3(1):187. https://doi.org/10.1038/s43856-023-00414-6 PMid:38114659

Höller A, Nguyen-Sträuli BD, Frauchiger-Heuer H, Ring A. Diagnostic and prognostic biomarkers of luminal breast cancer: Where are we now? Breast Cancer (Dove Med Press). 2023;15:525-40.

Kanyılmaz G, Yavuz BB, Aktan M, Karaağaç M, Uyar M, Fındık S. Prognostic importance of Ki-67 in breast cancer and its relationship with other prognostic factors. Eur J Breast Health. 2019;15(4):256-261. https://doi.org/10.5152/ejbh.2019.4778 PMid:31620685

Zhang H, Niu S, Chen H, Wang L, Wang X, Wu Y, et al. Radiomics signatures for predicting the Ki-67 level and HER-2 status based on bone metastasis from primary breast cancer. Front Cell Dev Biol. 2023;11:1220320. https://doi.org/10.3389/fcell.2023.1220320 PMid:38264355

Walker RA. Prognostic and Predictive Factors in Breast Cancer. New York: Informa Health Care; 2003:8-10. https://doi.org/10.1177/11782234241255211 PMid:38779417

Bustreo S, Osella-Abate S, Cassoni P, Donadio M, Airoldi M, Pedani F, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: A large case series study with a long-term follow-up. Breast Cancer Res Treat. 2016;157(2):363- 71. https://doi.org/10.1007/s10549-016-3817-9 PMid:27155668

Esmat E, Haidary AM, Saadaat R, Rizvi SN, Aleena S, Haidari M, et al. Association of hormone receptors and human epidermal growth factor receptor-2/neu expressions with clinicopathologic factors of breast carcinoma: A cross-sectional study in a tertiary care hospital, Kabul, Afghanistan. BMC Cancer. 2024;24(1):388. https://doi.org/10.1186/s12885-024-12129-5 PMid:38539179

Hu Q, Hu Y, Ai H, Xia L, Liu R, Ai T. Pre-operative MRI in evaluating pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer: A study focused on influencing factors of baseline clinical-pathological and imaging features. Front Oncol. 2024;14:1366613. https://doi.org/10.3389/fonc.2024.1366613 PMid:38826784

Liang Q, Ma D, Gao RF, Yu KD. Effect of Ki-67 Expression levels and histological grade on breast cancer early relapse in patients with different immunohistochemical-based subtypes. Sci Rep. 2020;10(1):7648. https://doi.org/10.1038/s41598-020-64523-1 PMid:32376868

Niță I, Nițipir C, Toma ȘA, Limbău AM, Pîrvu E, Bădărău IA, et al. Histological aspects and quantitative assessment of Ki67 as prognostic factors in breast cancer patients: Result from a single-center, cross sectional study. Medicina (Kaunas). 2020;56(11):600. https://doi.org/10.3390/medicina56110600 PMid:33182401

Rewcastle E, Skaland I, Gudlaugsson E, Fykse SK, Baak JP, Janssen EA. The Ki67 dilemma: investigating prognostic cut- offs and reproducibility for automated Ki67 scoring in breast cancer. Breast Cancer Res Treat. 2024;207(1):1-12. https://doi.org/10.1007/s10549-024-07352-4 PMid:38797793

Sun XB, Liu WW, Wang B, Yang ZP, Tang HZ, Lu S, et al. Correlations between serum lipid and Ki-67 levels in different breast cancer molecular subcategories. Oncol Lett. 2023;25(2):53. https://doi.org/10.3892/ol.2022.13639 PMid:36644143

Liang Q, Ma D, Gao RF, Yu KD. Effect of Ki-67 expression levels and histological grade on breast cancer early relapse in patients with different immunohistochemical-based subtypes. Sci Rep. 2020;10(1):7648. https://doi.org/10.1038/s41598-020-64523-1 PMid:32376868

Nielsen TO, Leung SC, Rimm DL, Dodson A, Acs B, Badve S, et al. Assessment of Ki67 in breast cancer: Updated recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 2021;113(7):808-19. https://doi.org/10.1093/jnci/djaa201 PMid:33369635

de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96(10):1504-13. https://doi.org/10.1038/sj.bjc.6603756 PMid:17453008

Alco G, Bozdogan A, Selamoglu D, Pilanci KN, Tuzlali S, Ordu C, et al. Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients. Oncol Lett. 2015;9(3):1046-1054. https://doi.org/10.3892/ol.2015.2852 PMid:25663855

Wang S, Zhang Q, Zhang T, Mao X. Invasive papillary carcinoma of the breast: A case report. Oncol Lett. 2024;28(1):300. https://doi.org/10.3892/ol.2024.14433 PMid:38765791

Oshiro C, Yamasaki M, Noda Y, Nishimae A, Takahashi H, Inaji H. Comparative evaluation of nuclear and histological grades as prognostic factors for invasive breast cancer. Breast Cancer. 2020;27(5):947-53. https://doi.org/10.1007/s12282-020-01093-0 PMid:32297249

Roudini K, Mirzania M, Yavari T, Seyyedsalehi MS, Nahvijou A, Zebardast J, et al. Neoadjuvant chemotherapy in patients with HER2-negative breast cancer: A report from clinical breast cancer registry of Iran. Arch Iran Med. 2024;27(4):206-15. https://doi.org/10.34172/aim.2024.30 PMid:38685847

Schwartz AM, Henson DE, Chen D, Rajamarthandan S. Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: a study of 161 708 cases of breast cancer from the SEER Program. Arch Pathol Lab Med. 2014;138(8):1048-52. https://doi.org/10.5858/arpa.2013-0435-OA PMid:25076293

Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008;26(19):3153-8. https://doi.org/10.1200/JCO.2007.15.5986 PMid:18490649

Bruno F, Arcuri D, Vozzo F, Malvaso A, Montesanto A, Maletta R. Expression and signaling pathways of nerve growth factor (NGF) and Pro-NGF in breast cancer: A systematic review. Curr Oncol. 2022;29(11):8103-20. https://doi.org/10.3390/curroncol29110640 PMid:36354700

Boers J, Eisses B, Zwager MC, Van Geel JJ, Bensch F, De Vries EF, et al. Correlation between histopathological prognostic tumor characteristics and [18F]FDG uptake in corresponding metastases in newly diagnosed metastatic breast cancer. Diagnostics (Basel). 2024;14(4):416. https://doi.org/10.3390/diagnostics14040416 PMid:38396455

Witt BL, Tollefsbol TO. Molecular, cellular, and technical aspects of breast cancer cell lines as a foundational tool in cancer research. Life (Basel). 2023;13(12):2311. https://doi.org/10.3390/life13122311 PMid:38137912

Ferraguti G, Terracina S, Tarani L, Fanfarillo F, Allushi S, Caronti B, et al. Nerve growth factor and the role of inflammation in tumor development. Curr Issues Mol Biol. 2024;46(2):965-89. https://doi.org/10.3390/cimb46020062 PMid:38392180

Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, et al. (2015). High Ki-67 expression and low progesterone receptor expression could independently lead to a worse prognosis for postmenopausal patients with estrogen receptor- positive and HER2-negative breast cancer. Clin Breast Cancer, 15(3), 204-211. https://doi.org/10.1016/j.clbc.2014.12.007 PMid:25600243